# Abbott Laboratories (ABT) Financial Model Free Excel 3-statement financial model and company analysis for Abbott Laboratories. - Canonical: https://finamodel.com/companies/abbott-laboratories - Industry: Medical Devices - Downloadable model: Yes - Excel download: https://finamodel.com/company-models/ABT.xlsx ## Model Purpose This model projects Abbott Laboratories' future cash flows and earnings to determine its equity valuation, with a specific focus on assessing the financial impact and integration of the pending Exact Sciences acquisition closing in Q2 2026. ## Company Overview Abbott Laboratories is a diversified global healthcare company that discovers, develops, manufactures, and sells a broad line of healthcare products. The company operates across four primary segments: Medical Devices (approx. 48% of revenue), Diagnostics (approx. 20%), Nutrition (approx. 19%), and Established Pharmaceuticals (approx. 13%). Abbott generates over 60% of its revenue outside the United States, making it highly exposed to global healthcare trends and foreign exchange movements. The business model is a mix of asset-heavy manufacturing (Nutrition, Pharmaceuticals) and high-margin, innovation-driven technology (Medical Devices, Diagnostics). Abbott holds market-leading positions in continuous glucose monitoring (FreeStyle Libre), structural heart devices, core laboratory diagnostics, and adult nutrition (Ensure). Recent major events include the discontinuation of the ZonePerfect nutrition line in 2024, the complete phase-out of COVID-19 testing revenues, and the November 2025 announcement to acquire Exact Sciences for over USD 3 billion in annual revenue, expected to close in Q2 2026. ## Revenue Deep Dive ### Medical Devices - **Segment name:** Medical Devices - **Revenue driver formula:** Volume of Devices Sold x Average Selling Price - **Historical growth rate:** 12% to 14% - **Key growth levers and headwinds:** Driven heavily by Diabetes Care (FreeStyle Libre continuous glucose monitors, which reached a USD 8 billion run rate in 2025) and Electrophysiology (Volt PFA System). Headwinds include hospital capital spending constraints and pricing pressure in competitive cardiovascular markets. - **Pricing dynamics:** Highly competitive but supported by continuous innovation and new product approvals. - **Revenue recognition notes:** Recognised at the point of sale or delivery to hospitals and distributors. - **Seasonality:** Q4 is typically the strongest quarter due to hospital budget flushes and elective procedure scheduling. ### Diagnostics - **Segment name:** Diagnostics - **Revenue driver formula:** Number of Tests/Instruments Placed x Revenue per Test/Instrument - **Historical growth rate:** Base business growing 4% to 6%; overall segment previously declined due to the loss of COVID-19 testing revenue. - **Key growth levers and headwinds:** Growth is driven by the Alinity family of diagnostic systems and the upcoming integration of Exact Sciences (Cologuard). The primary historical headwind (COVID-19 testing decline) has fully washed out as of 2025. - **Pricing dynamics:** Contractual and volume-based, with long-term agreements for core laboratory placements. - **Revenue recognition notes:** Instrument sales recognised upon installation; reagent and consumable sales recognised upon delivery. - **Seasonality:** Mild seasonality with higher respiratory testing volumes in Q1 and Q4. ### Nutrition - **Segment name:** Nutrition - **Revenue driver formula:** Volume of Formula/Shakes Sold x Price per Unit - **Historical growth rate:** 3% to 5% (adjusted for the ZonePerfect discontinuation). - **Key growth levers and headwinds:** Adult Nutrition (Ensure, Protality) is driving growth due to ageing populations and GLP-1 muscle-preservation trends. Pediatric Nutrition has recovered market share following the 2022 infant formula recall. - **Pricing dynamics:** Consumer retail pricing power, though subject to commodity cost inflation (dairy, soy). - **Revenue recognition notes:** Recognised upon shipment to retail customers and distributors. - **Seasonality:** Relatively stable throughout the year. ### Established Pharmaceuticals (EPD) - **Segment name:** Established Pharmaceutical Products - **Revenue driver formula:** Volume of Branded Generics x Price per Pill/Treatment - **Historical growth rate:** 8% to 10% organic growth. - **Key growth levers and headwinds:** 100% of sales are outside the US, focused entirely on emerging markets (Latin America, India, Southeast Asia). Growth is driven by rising middle-class healthcare access. The main headwind is foreign exchange translation. - **Pricing dynamics:** Regulated pricing in many emerging markets, offset by volume growth. - **Revenue recognition notes:** Recognised upon delivery to wholesalers and pharmacies. - **Seasonality:** Generally stable, with slight variations based on local market flu seasons. ## Cost Structure ### Variable Costs / COGS - COGS includes raw materials (plastics, electronics, dairy, active pharmaceutical ingredients), direct manufacturing labour, and global supply chain logistics. - Gross margin has expanded recently, reaching approximately 55.9% on an adjusted basis in 2024/2025, up from the low 50s in previous years. - Key input costs include electronic components for medical devices and agricultural commodities for nutrition. - COGS scales with operating leverage; as the high-margin Medical Devices segment becomes a larger portion of total revenue, consolidated gross margins naturally expand. ### Operating Expenses - **R&D:** Typically runs at 6.0% to 6.5% of revenue. It covers clinical trials, software development for connected devices (FreeStyle Libre), and next-generation diagnostic platforms. - **SG&A:** Typically runs at 26.0% to 27.0% of revenue. This includes a massive global sales force for medical devices and pharmaceuticals, plus consumer marketing for the Nutrition segment. - **Depreciation & Amortisation:** Significant amortisation of intangible assets related to historical acquisitions (St. Jude Medical, Alere) and soon Exact Sciences. - **Stock-Based Compensation:** Material but standard for the sector, typically excluded from adjusted earnings metrics. - **Restructuring / one-time charges:** Frequent. Abbott regularly records restructuring charges for facility consolidations and product line exits (e.g., ZonePerfect in 2024). ### Margin Profile - Gross margin: 54% to 57% (adjusted). - Operating margin: 19% to 21% (adjusted). - Net margin: 14% to 16% (adjusted). - Margin trend is expanding due to the mix shift towards high-margin Medical Devices and continuous gross margin improvement initiatives. ## Balance Sheet Structure - Total assets are in the range of USD 70 billion to USD 75 billion. - Key assets include substantial Goodwill and Intangible Assets (historically over 40% of total assets) due to a history of large acquisitions. This will increase significantly upon closing the Exact Sciences deal. - Working capital profile: - Days Sales Outstanding (DSO): 55 to 65 days. - Days Inventory Outstanding (DIO): 85 to 95 days. - Days Payable Outstanding (DPO): 55 to 65 days. - Net working capital is generally positive, requiring cash to fund inventory builds for new product launches. - PP&E consists of global manufacturing facilities, particularly new expansions in Mexico and Georgia for cardiovascular devices. - Operating leases are material but standard for global office and warehouse footprints. ## Capital Expenditure & Investment - Capex typically runs at 4.0% to 5.0% of revenue. - The split is heavily weighted towards growth capex, funding new manufacturing lines for FreeStyle Libre and cardiovascular devices. - M&A pattern: Abbott is a transformational acquirer. After a quiet period following the St. Jude and Alere deals, the company announced the acquisition of Exact Sciences in late 2025. - Typical acquisition multiples are high for high-growth assets (Exact Sciences was acquired for its USD 3 billion revenue base growing in the high teens). ## Debt & Capital Structure - Total debt historically sits around USD 15 billion, but this will change dramatically to fund the Exact Sciences acquisition in 2026. - Debt/EBITDA ratio is typically managed conservatively (target below 2.0x), though it spikes temporarily following major M&A. - Credit rating is strong investment grade (A-tier). - Key debt instruments include long-term senior unsecured notes. - The company has an active share repurchase programme, with a USD 7 billion authorisation announced in October 2024. - Abbott is a "Dividend King" with 54 consecutive years of dividend increases. The payout ratio is typically 40% to 45% of adjusted earnings, with a 6.8% increase announced for 2026. ## Cash Flow Characteristics - Operating cash flow conversion is excellent, typically exceeding 1.0x of GAAP net income due to heavy non-cash amortisation charges. - Free cash flow margin generally ranges from 15% to 18%. - Major non-cash items bridging net income to OCF include depreciation, amortisation of acquisition-related intangibles, and stock-based compensation. - Working capital is a moderate use of cash as the company scales its Medical Devices manufacturing. - The cash tax rate closely mirrors the adjusted effective tax rate of approximately 14.0%. ## Sheet Structure 1. **Assumptions:** Hardcoded drivers for macroeconomic inputs, segment growth rates, margin targets, and M&A deal terms. 2. **Scenarios:** Scenario toggles (Base, Bull, Bear) driving the Exact Sciences integration speed and FreeStyle Libre market penetration. 3. **Income Statement:** Consolidated P&L down to GAAP and Adjusted EPS. 4. **Segment Revenue:** Detailed build for Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. 5. **M&A Pro Forma:** Dedicated schedule for the Exact Sciences acquisition, calculating the stub period for 2026, purchase price allocation, and new debt issuance. 6. **Balance Sheet:** Standard assets, liabilities, and equity, with specific lines for Goodwill and Intangible Assets. 7. **Cash Flow Statement:** OCF, CFI, CFF, and free cash flow generation. 8. **Working Capital:** Schedules for Accounts Receivable, Inventory, and Accounts Payable based on days outstanding. 9. **Debt Schedule:** Tranche-by-tranche debt build, including the new bridge/term loans required for the 2026 M&A. 10. **Depreciation & Amortisation:** Waterfall schedules for existing PP&E, new capex, and acquired intangibles. 11. **Shareholders Equity:** Retained earnings, share repurchases (tracking the USD 7 billion authorisation), and dividend payouts. 12. **DCF Valuation:** Unlevered free cash flow build, WACC calculation, and terminal value. ## Key Financial Relationships 1. `Medical Devices Revenue = Diabetes Care Revenue + Cardiovascular Revenue + Neuromodulation Revenue` 2. `Diabetes Care Revenue = FreeStyle Libre Users x Annual Revenue Per User` 3. `Diagnostics Revenue = Core Laboratory + Molecular + Point of Care + Rapid Diagnostics + Exact Sciences Pro-Forma Revenue` 4. `Exact Sciences Pro-Forma Revenue = Standalone Exact Sciences Projected Revenue x (Months Post-Close / 12)` 5. `Nutrition Revenue = Pediatric Nutrition + Adult Nutrition` 6. `Established Pharmaceuticals Revenue = Key Emerging Markets Revenue + Other Markets Revenue` 7. `Consolidated Revenue = Medical Devices + Diagnostics + Nutrition + Established Pharmaceuticals` 8. `Adjusted Gross Profit = Consolidated Revenue - Adjusted COGS (excluding restructuring and amortisation of intangibles)` 9. `Adjusted Operating Income = Adjusted Gross Profit - Adjusted SG&A - Adjusted R&D` 10. `Effective Tax Rate = Adjusted Provision for Taxes / Adjusted Earnings Before Taxes` 11. `Free Cash Flow = Operating Cash Flow - Capital Expenditures` 12. `Dividend Payout = Dividends Per Share x Total Outstanding Shares` ## Cross-Sheet Dependencies - The **M&A Pro Forma** sheet is the critical chain for 2026 onwards. It feeds new revenue into the **Segment Revenue** sheet, adds new operating expenses to the **Income Statement**, increases Goodwill on the **Balance Sheet**, and triggers new borrowing on the **Debt Schedule**. - The **Segment Revenue** sheet feeds the top line of the **Income Statement**. - The **Income Statement** generates Net Income, which flows to the top of the **Cash Flow Statement** and into Retained Earnings on the **Balance Sheet**. - The **Debt Schedule** calculates interest expense, which flows back to the **Income Statement** (creating a circularity that must be managed with a toggle or iterative calculation). ## Sign Convention - Revenue and operating metrics (Gross Profit, EBITDA, Net Income) are entered and displayed as positive numbers. - Expenses (COGS, SG&A, R&D, Interest Expense) are entered as positive numbers and subtracted in formulas. - On the Cash Flow Statement, cash inflows are positive and cash outflows (Capex, Dividends, Share Repurchases) are negative. - Balance sheet items are positive balances. ## Things Most Likely to Go Wrong 1. Failing to exclude COVID-19 testing revenue from historical 2021 to 2024 data when calculating base organic growth rates, which will severely distort trend analysis. 2. Mishandling the Exact Sciences acquisition closing in Q2 2026, which requires a partial-year stub adjustment for revenue and operating expenses. 3. Ignoring the margin dilution impact of the Exact Sciences acquisition, as Exact Sciences historically operated at lower operating margins than Abbott's base business. 4. Overlooking the discontinuation of the ZonePerfect product line in 2024, which artificially depresses historical Nutrition segment growth if not adjusted. 5. Miscalculating foreign exchange headwinds, as the Established Pharmaceuticals segment is entirely international and highly sensitive to emerging market currency fluctuations. 6. Confusing GAAP and Adjusted earnings; Abbott reports significant acquisition-related amortisation and restructuring charges that must be added back to reflect cash earnings. 7. Underestimating the cash required for the Exact Sciences acquisition, which will significantly alter the debt schedule and interest expense in the second half of 2026. 8. Failing to model the continuous dividend increases; Abbott is a Dividend King and a flat dividend assumption will misrepresent capital allocation. 9. Incorrectly modelling share repurchases; the model must account for the USD 7 billion repurchase programme authorised in October 2024. ## Validation Checks 1. Adjusted Gross Margin should remain in the 55.0% to 57.0% range; flag if outside this band. 2. R&D as a percentage of revenue should consistently run between 6.0% and 6.5%. 3. The Medical Devices segment must account for at least 48% of total revenue by 2026. 4. Dividend per share must increase year-over-year (minimum 5% growth) to maintain Dividend King status. 5. Balance sheet must balance: Total Assets = Total Liabilities + Equity in every projected period. 6. OCF/Net Income conversion should be >1.1x due to heavy non-cash amortisation add-backs. 7. Debt/EBITDA should spike in 2026 due to the Exact Sciences deal but must deleverage below 2.5x by 2028. 8. Effective tax rate should remain near the 14.0% adjusted guidance level. ## Key Assumptions (Default Values) | Assumption | Default Value | Unit | Rationale | |---|---|---|---| | Medical Devices Base Growth | 12.0 | % | Driven by FreeStyle Libre and Electrophysiology momentum | | Diagnostics Base Growth | 4.5 | % | Core laboratory growth, excluding COVID-19 and Exact Sciences | | Nutrition Growth | 4.0 | % | Steady growth led by Adult Nutrition (Ensure) | | Established Pharma Growth | 8.5 | % | Strong organic volume growth in emerging markets | | Adjusted Gross Margin | 56.0 | % | Reflects recent margin expansion initiatives and product mix | | Adjusted R&D Margin | 6.1 | % | Historical average required to maintain product pipeline | | Adjusted SG&A Margin | 26.3 | % | Historical average required for global sales footprint | | Adjusted Tax Rate | 14.0 | % | Management guidance for adjusted effective tax rate | | Capex as % of Revenue | 4.5 | % | Required to fund new manufacturing facilities in Mexico and Georgia | | Dividend Per Share (2026) | 2.36 | USD | Reflects the announced 6.8% increase for 2026 | | Annual Share Repurchases | 1,500 | USD Millions | Steady execution of the USD 7 billion authorisation | | Discount Rate (WACC) | 7.5 | % | Standard cost of capital for a diversified, large-cap healthcare equipment firm | | Terminal Growth Rate | 2.5 | % | Aligns with long-term global healthcare spending growth | ## Data Sources & Benchmarks - **Filings:** SEC EDGAR (Abbott Laboratories CIK: 0000001800), Abbott Investor Relations website (abbottinvestor.com). - **Key Peers:** Medtronic (MDT), Boston Scientific (BSX), Johnson & Johnson (JNJ) for Medical Devices; Roche (RHHBY) for Diagnostics. - **Industry Data:** IQVIA for pharmaceutical prescription volumes in emerging markets; EvaluateMedTech for medical device market share data. - **Consensus Estimates:** FactSet or Bloomberg for validation of 2026 and 2027 revenue and EPS estimates. ## Sources - Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook (January 22, 2026) - Abbott 2025 Annual Report (March 2026) - Abbott Reports Fourth-Quarter and Full-Year 2024 Results (January 22, 2025) - Abbott Reports Third-Quarter 2024 Results and Raises Midpoint of Full-Year EPS Guidance Range (October 16, 2024) - Abbott Reports Second-Quarter 2024 Results and Raises Full-Year Guidance (July 18, 2024) - Abbott Reports First-Quarter 2024 Results (April 17, 2024) - Form 10-Q for Abbott Laboratories filed 05/02/2024 - Earnings call: Abbott reports robust Q4 results, optimistic 2024 outlook (January 24, 2024) --- ## Frequently asked questions ### What does Abbott Laboratories do? Abbott Laboratories is a diversified global healthcare company that discovers, develops, manufactures, and sells a broad line of healthcare products. It operates across four primary segments: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. ### How does Abbott Laboratories generate revenue? Abbott Laboratories generates revenue primarily through its Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals segments, with Medical Devices contributing approximately 48% of its revenue. Over 60% of its revenue comes from outside the United States, making it exposed to global healthcare trends. ### What is Abbott Laboratories' typical capital expenditure as a percentage of revenue? Abbott Laboratories typically allocates 4.0% to 5.0% of its revenue towards capital expenditures. This spending is heavily weighted towards growth capex, funding new manufacturing lines for products like FreeStyle Libre and cardiovascular devices. ### How does the Exact Sciences acquisition impact Abbott Laboratories' financial model? The Exact Sciences acquisition, expected to close in Q2 2026, is a key focus of Abbott's financial model, specifically assessing its financial impact and integration. This acquisition adds over USD 3 billion in annual revenue and will significantly increase Goodwill and Intangible Assets on the balance sheet. ### What is the primary purpose of a financial model for Abbott Laboratories? The primary purpose of a financial model for Abbott Laboratories is to project its future cash flows and earnings to determine its equity valuation. A specific focus is placed on assessing the financial impact and integration of the pending Exact Sciences acquisition. ### Can I download an Excel financial model for Abbott Laboratories? Yes, an Excel financial model for Abbott Laboratories is available for download. This model projects the company's financials from FY2026 to FY2030. [Interactive forecast calculator](https://finamodel.com/companies/abbott-laboratories/forecast)